LLY Eli Lilly and Company
Company Analysis
Latest News
🟢 Eli Lilly and Company is trading 3.4% up today after positive late-stage obesity drug data
Eli Lilly and Company is trading 3.4% up at $1,170.00 after releasing highly positive late-stage clinical data for its next-generation obesity drugs presented...
🟢 Eli Lilly surges 4.4% after presenting highly positive Phase 3 data for new obesity drugs
Eli Lilly and Company (LLY) is trading at $1181.00 (+4.4%) in pre-market sessions, driven by the release of highly positive new clinical data for its...
🟢 Eli Lilly and Company is trading 3.24% up today on obesity franchise momentum and strong institutional demand
Eli Lilly and Company is trading 3.24% up at $1,161.70 on continued momentum in its obesity and diabetes franchise and strong institutional demand. • Renewed...
🟢 Eli Lilly and Company is trading 5.2% up today on obesity drug enthusiasm and strong institutional demand
Eli Lilly and Company is trading 5.2% up at $1135.25 following fresh enthusiasm around its obesity and diabetes franchise and evidence of strong institutional...
Eli Lilly Surges 4.6% on Weight-Loss Drug Euphoria and Big-Money Buying — But Can the Stock Keep Outrunning Its Own Hype?
Shares of Eli Lilly jumped 4.6% to $1,127.99 on June 4, snapping a week-long slide that saw the stock drop from $1,126.80 to $1,064.15 in just five sessions....
🟢 Eli Lilly is trading 4.6% up today on a new $1.9B genetic medicine deal and a Weight Watchers partnership
Eli Lilly and Company is trading 4.6% up at $1127.99 following the announcement of a major research partnership and expanded access for its weight-loss drug...
🟢 Eli Lilly and Company is trading 4.5% up today on GLP-1 optimism and institutional dip-buying
Eli Lilly and Company is trading 4.5% up at $1126.80 following strong premarket interest and persistent optimism surrounding its GLP-1 obesity and diabetes...
Eli Lilly Halves €2.3B German Plant Investment, Citing Healthcare Reforms
Eli Lilly is halving its planned €2.3 billion investment in a new manufacturing facility in Alzey, Germany. The company will reduce the number of projected...
Eli Lilly signs $1.9B RNA editing deal, targeting kidney disease
Eli Lilly signed a research and licensing agreement with Ascidian Therapeutics to develop genetic medicines for kidney diseases. The total deal value reaches...
Eli Lilly inks $4.2B in Asian drug deals to bolster pipeline
Eli Lilly and Company signed two significant licensing agreements in Asia on June 1, 2026. The company partnered with China’s Haisco Pharmaceutical in a...
Eli Lilly signs $3 billion Haisco deal to boost drug discovery
Eli Lilly partnered with Chinese drugmaker Haisco Pharmaceutical to develop innovative medicines across multiple therapeutic areas. The collaboration focuses...
Eli Lilly cuts lung cancer recurrence risk 83% in landmark Retevmo trial
Eli Lilly reported that its targeted therapy Retevmo significantly improved outcomes in the Phase 3 LIBRETTO-432 trial. The drug reduced the risk of disease...
Eli Lilly showcases Foundayo data, beating oral semaglutide in weight loss
Eli Lilly and Company will present new cardiometabolic data at the American Diabetes Association's 86th Scientific Sessions from June 5-8. The presentations...
Eli Lilly Challenges Pfizer, Reporting Positive Bladder Cancer Drug Data
Eli Lilly presented Phase 1 trial results for its antibody-drug conjugate LY4052031 at the ASCO Annual Meeting. The drug treats advanced or metastatic...
🔴 LLY is trading 3% down today on profit-taking after obesity-drug reimbursement wins
LLY is trading 3% down at $1092.74 as investors lock in gains following a sharp rally driven by positive obesity-drug developments. • The pullback comes after...
Eli Lilly secures full PBM coverage for Zepbound, ending CVS exclusion
Eli Lilly secured coverage for obesity drugs Zepbound and Foundayo from all three major U.S. pharmacy benefit managers. CVS Caremark will add both medications...
Eli Lilly Price Target Lifted to $1,251 at BofA on Weight-Loss Drug Optimism
BofA Securities raised its price target for Eli Lilly (LLY) to $1,251 from $1,133. The bank maintained its "Buy" rating on the stock. A positive outlook for...
Eli Lilly buys three biotechs for $4 billion, returning to vaccines
Eli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics, and Vaccine Company. The combined acquisitions total nearly $4 billion. This strategy...
Eli Lilly cuts cholesterol 62% with gene-editing therapy, sustaining 18-month results
Eli Lilly reported positive Phase 1b Heart-2 trial results for VERVE-102, an investigational gene-editing therapy for high-risk cardiovascular patients. A...
Eli Lilly Achieves 28% Weight Loss in Trial, Rivaling Bariatric Surgery
Eli Lilly announced Thursday that its experimental obesity drug, retatrutide, met all primary and secondary endpoints in a pivotal Phase 3 trial. The...